"CORolla® - a disruptive ""spring like"" metallic device for permanent treatment of diastolic heart failure."

Informations projet

CORolla

N° de convention de subvention: 832168

DOI

10.3030/832168

Projet clôturé

Date de signature de la CE 28 Novembre 2018

Date de début 1 Novembre 2018

Date de fin 28 Février 2019

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

CORASSIST CARDIOVASCULAR LTD
Israel

Periodic Reporting for period 1 - CORolla (CORolla® - a disruptive "spring like" metallic device for permanent treatment of diastolic heart failure.)

Période du rapport: 2018-11-01 au 2019-02-28

Résumé du contexte et des objectifs généraux du projet

If a patient has diastolic heart failure, his left ventricle becomes stiffer than normal. Because of that, his heart can't relax the way it should. When it pumps, it can't fill up with blood as it's supposed to. Because there's less blood in the ventricle, less blood is pumped out to the body. This disfunction has very negative influence on the quality of life. It causes shortness of breath, tiredness, weakness, swelling of feet, ankles, legs, or abdomen, lasting cough or wheezing, fast or irregular heartbeat, dizziness, confusion, nausea, lack of appetite. It may lead to many complications including anemia, impaired kidney function or stroke. With diastolic heart failure, currently, there is no available treatment for the condition. The current practice involves only identifying and treating comorbidities (i.e. conditions such as hypertension, diabetes, etc.) associated with heart failure and symptomatic relief medications like use of diuretics. CORolla® - an elastic "spring-like" metallic device (Figure 1) which is implanted inside the Left Ventricle (LV) of the heart in a minimally invasive procedure. It is innovative device-based treatment for HFpEF (Heart failure with preserved ejection fraction) aimed at providing diastolic heart failure treatment. The overall objective is to clinically validate the medical device and reach market readiness.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

During the feasibility assessment, CorAssist has completed a full analysis of the technical, clinical and business potential of their CORolla® medical implantable device. Throughout the project, CorAssist has greatly expanded their knowledge regarding the clinical validation and regulatory approval required for the European market launch. The key technical milestone achieved during the project was the approval of safety and feasibility clinical investigation which would be sufficient to apply for the CE Mark. CorAssist also received and disseminated the results from first patient implanted with CORolla®.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

CORolla® is the first device designed to improve the impaired diastolic function which affects more than 13 million people worldwide. It is implanted in a one-time procedure improving patient’s quality of life, reducing morbidity and the need for frequent hospitalizations.

CORolla device

CORolla spring to treat diastolic heart failure